Practical Therapeutic Drug Management in HIV‐Infected Patients: Use of Population Pharmacokinetic Models Supplemented by Individualized Bayesian Dose Optimization
Open Access
- 1 September 2008
- journal article
- case report
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (9) , 1081-1091
- https://doi.org/10.1177/0091270008321789
Abstract
Individualized, model‐based, target‐oriented optimal concentration‐controlled dosing of HIV medications can be beneficial to patients for whom there are limited dosing guidelines, such as children, adolescents, or patients with altered physiologic function. Barriers to this approach include lack of training, expertise, and access to appropriate software to assist the clinician. The authors present 4 illustrative clinical cases of HIV‐infected patients whose therapy was optimized using population pharmacokinetic models (here generated from published studies) and supplemented by individualized Bayesian adaptive control of dosage regimens as implemented in the MM‐USCPACK software. These 4 cases illustrate how clinicians can maximize therapeutic success in (1) patients with reduced drug clearance, (2) young adolescents transitioning to adult physiology, (3) patients with dose‐dependent toxicity, and (4) adolescents with limited therapeutic options.Keywords
This publication has 50 references indexed in Scilit:
- Practical Therapeutic Drug Management in HIV‐Infected Patients: Use of Population Pharmacokinetic Models Supplemented by Individualized Bayesian Dose OptimizationThe Journal of Clinical Pharmacology, 2008
- Drug interactions in the management of HIV infection: an updateExpert Opinion on Pharmacotherapy, 2007
- Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV-infected Children Participating in an Area-under-the-curve Controlled TrialClinical Pharmacology & Therapeutics, 2007
- Efavirenz and Nevirapine in HIV-1 InfectionClinical Pharmacokinetics, 2007
- Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 2006
- Quality Assurance Program for Pharmacokinetic Assay of Antiretrovirals: ACTG Proficiency Testing for Pediatric and Adult Pharmacology Support Laboratories, 2003 to 2004Therapeutic Drug Monitoring, 2006
- Pharmacokinetics of nelfinavir in HIV‐1‐infected pregnant and nonpregnant womenBritish Journal of Clinical Pharmacology, 2006
- Parametric and Nonparametric Population MethodsClinical Pharmacokinetics, 2006
- FosamprenavirClinical Pharmacokinetics, 2006
- The Monte Carlo MethodJournal of the American Statistical Association, 1949